AMDL Inc has received approval to sell and market its DR-70 cancer detection test throughout Canada. The Therapeutic Products Directorate, Medical Devices Bureau, Canada, has licensed the sale and marketing of AMDL's DR-70 cancer detection test kit throughout Canada.

"This approval is an important step forward in keeping with our business strategy and marks a major milestone for AMDL," said Gary L. Dreher, President & CEO. "Already, several potential distributors have shown serious interest in the Canadian market and AMDL can now accelerate those discussions. This is one of several efforts we have been concentrating on to globalize the marketing of our products."

AMDL is a theranostics company, involved in the detection and treatment of the same disease, cancer. The company is the inventor, developer and worldwide marketer through distribution agreements of the DR-70 non-invasive cancer blood test, which has demonstrated its ability to detect the presence in humans of up to 13 cancers 84 per cent of the time overall.

Clinical trials of the DR-70 have been conducted in China, Canada, Taiwan and Turkey. Cancers that can be detected are lung, colon, breast, stomach, liver, rectum, ovary, cervix, esophagus, thyroid, pancreas, trophoblast and malignant lymphoma. DR-70 can detect many kinds of cancer using a single tube of blood, reducing the need for costly, multiple tests.

AMDL also owns a combination immunogene therapy technology that is a possible treatment for those already diagnosed with cancer and could eventually be used as a vaccine to protect patients known to be at risk because of a family history for certain types of cancer. The combination therapy both builds the body's immune system and destroys cancer cells.